Zcash is showing signs of stabilization after a prolonged downward move, with price action consolidating near key resistance levels. However, a breakout from a Zcash is showing signs of stabilization after a prolonged downward move, with price action consolidating near key resistance levels. However, a breakout from a

Zcash (ZEC) Price Prediction: Descending Channel Breakout Suggest a Rally to $1,000

2025/12/22 01:31
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]
  • Zcash broke its long-term descending channel, signaling a potential bullish reversal.
  • ZEC finds short-term support around $417–$423, with potential resistance between $470 and $580.
  • Major ZEC targets of $470, $580, $740, and $1,000 highlight increasing bullish momentum and investor confidence.

Zcash is showing signs of stabilization after a prolonged downward move, with price action consolidating near key resistance levels. However, a breakout from a long-term descending structure suggests a possible shift in an upward direction.

At the time of writing, ZEC is trading at $433.84, supported by a 24-hour trading volume of $467.52 million and a market capitalization of $7.13 billion. Its price has slightly dropped by 3.12% over the last 24 hours, but it is still up by 7.09% over the last week.

Source: CoinMarketCap

Also Read: Zcash (ZEC) Price Shows Strength With Technical Signals Hinting $480 Break

ZEC Breakout Imminent as price Breaks Key EMAs

Zcash (ZEC) shows consolidation after a recent downtrend from highs near $750. Currently, it is moving slightly below the upper Bollinger Band ($482), suggesting buyers are testing resistance. The 20-day EMA ($423) supports near-term stability, while the 50-day EMA ($417) reinforces this consolidation zone. Momentum is building cautiously.

Source: TradingView

Support levels are strong for the longer term, with the 100-day EMA at $347 and the 200-day EMA at $247, both of which are well away from the current prices. Bollinger Bands are narrowing, with low volatility, which could lead to a breakout. A breakout above the upper EMA band could lead to prices reaching $470-$580, while a fall below $416 could lead to a test at $347.

ZEC Descending Wedge Signals a Potential Rally to $1,000

According to the crypto analyst Jonathan Carter, Zcash (ZEC) has now broken out of the long-standing descending channel on its 8-hour chart, which is an indication of a reversal of a trend. Breaking out of a descending channel marks a point where a consolidating phase is initiated. During this phase, prices become stable, and market momentum is revived.

In this consolidation, ZEC digests recent gains, making a solid base for future upward momentum. Traders are given time to determine market sentiment in preparation for future rapid upward movements. It is essential to exercise patience in this phase, as haste can be costly. It has been noted that observant behavior in this stage can result in immense gains in the future.

Source: Jonathan Carter

If ZEC picks up momentum, major resistance levels are $470, $580, $740, and finally $1,000. These are just indicative of milestone levels of steadily rising momentum among investors. A breakthrough past these points may generate further momentum. Investors are closely following this, as a period of consolidation at present may mean a major rally in the future.

Also Read: Zcash Whale Withdrawals Signal Accumulation as ZEC Price Eyes $695 Breakout

Market Opportunity
Zcash Logo
Zcash Price(ZEC)
$209.69
$209.69$209.69
-1.05%
USD
Zcash (ZEC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09